Pancreatic Cancer Research

ResearcherTel Aviv UniversityActive in the last 2 years

Dirk Arnold

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2392-599X; OpenAlex author ID A5052808201. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2019: 2 papers · 2020: 3 papers · 2021: none · 2022: 2 papers · 2023: none · 2024: 1 paper

Papers 8

  1. Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pan… Co-author DOI 10.1158/1078-0432.ccr-24-0645↗
  2. Platinum-Based Chemotherapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: Summary of Evidence and Application in Clinical Practice. First author DOI 10.1159/000527692↗
  3. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic C… Co-author DOI 10.1200/jco.21.01604↗
  4. Severe Nonbacterial Thrombotic Endocarditis Resulting in Aortic Valve Insufficiency and Multiple Small Strokes in a Patient With Metastatic Pancreatic Cancer: … Last author DOI 10.1016/j.clcc.2020.06.001↗
  5. Bratislava Statement: consensus recommendations for improving pancreatic cancer care. First author DOI 10.1136/esmoopen-2020-001051↗
  6. Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the… Co-author DOI 10.1200/jco.19.01890↗
  7. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. Co-author DOI 10.1056/nejmoa1903387↗
  8. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Co-author DOI 10.1093/annonc/mdz406↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eric Van Cutsem · 5 shared papers, 2019–2024 · strength 0.54
  2. Anke Reinacher‐Schick · 4 shared papers, 2019–2022 · strength 0.45
  3. Daniel Hochhauser · 4 shared papers, 2019–2022 · strength 0.36
  4. Talia Golan · 4 shared papers, 2019–2022 · strength 0.36
  5. Hedy Lee Kindler · 4 shared papers, 2019–2022 · strength 0.36
  6. Michele Reni · 4 shared papers, 2019–2022 · strength 0.36
  7. Pascal R. Hammel · 4 shared papers, 2019–2022 · strength 0.36
  8. Teresa Mercade Macarulla · 4 shared papers, 2019–2022 · strength 0.36
  9. Michael J. Hall · 3 shared papers, 2019–2022 · strength 0.29
  10. Joon Oh Park · 3 shared papers, 2019–2022 · strength 0.29
  11. Eileen Mary O'Reilly · 3 shared papers, 2019–2022 · strength 0.27
  12. Do‐Youn Oh · 3 shared papers, 2019–2022 · strength 0.27
  13. Giampaolo Tortora · 3 shared papers, 2019–2022 · strength 0.27
  14. Hana Algül · 3 shared papers, 2019–2022 · strength 0.27
  15. Marino Venerito · 1 shared paper, 2022 · strength 0.19
  16. Thomas Theodor Werner Seufferlein · 1 shared paper, 2022 · strength 0.19
  17. Ahmad Hussein Awada · 1 shared paper, 2024 · strength 0.17
  18. Rikke Løvendahl Eefsen · 1 shared paper, 2024 · strength 0.17
  19. Per Pfeiffer · 1 shared paper, 2024 · strength 0.17
  20. Maike Collienne · 1 shared paper, 2020 · strength 0.16
  21. Stefano Partelli · 1 shared paper, 2020 · strength 0.08
  22. Božena Smolková · 1 shared paper, 2020 · strength 0.08
  23. Thomas Baptist Brunner · 1 shared paper, 2020 · strength 0.08
  24. Francesco Sclafani · 1 shared paper, 2020 · strength 0.08
  25. Joan Prades · 1 shared paper, 2020 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.